Stockreport

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Nuvation Bio Inc. Class A  (NUVB) 
PDF Protocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now completeThe currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma w [Read more]